Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction
- 1 July 2001
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 74 (1) , 26-32
- https://doi.org/10.1007/bf02982546
Abstract
Graft-versus-host disease (GVHD) is the major complication after allogeneic hemopoietic stem cell transplantation. GVHD is destructive by itself and sets the stage for other sequelae, in particular, overwhelming infections. Recent investigations have improved our understanding of the underlying pathophysiology of GVHD. There are now compelling data on the role of host tissue destruction as the initial insult, extensive interactions of cellular donor and host components, a complex network of cytokines, adhesion molecules, and other components in the development of GVHD. The improved understanding of interactions among various signals is likely to allow for the development of new prophylactic strategies. A review of the data shows, however, that results are very dependent upon the models used. It is difficult or impossible to separate completely the discussion of cytokines that affect hemopoietic cells from discussion of cytokines that exert effects on immune cells. Furthermore, secondary effects on immune cells via hemopoietic cells complicate the picture. Application of the principles of cytokine signaling to the clinical setting may necessitate new trial design structures that take into consideration donor and host characteristics as well as the kinetics of GVHD development.Keywords
This publication has 85 references indexed in Scilit:
- AsthmaNew England Journal of Medicine, 2001
- Decreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatmentBone Marrow Transplantation, 2000
- Graft‐versus‐host‐disease‐associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathwayImmunology, 2000
- Interleukin-11 reduces T-cell-dependent experimental liver injury in miceHepatology, 1999
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cellsBone Marrow Transplantation, 1998
- Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.Journal of Clinical Investigation, 1998
- Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlatesBone Marrow Transplantation, 1997
- A PHASE I-II STUDY EVALUATING THE MURINE ANTI-IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASETransplantation, 1990
- TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH MONOCLONAL ANTIBODY TO IL-2 RECEPTORThe Lancet, 1988